Online citations, reference lists, and bibliographies.

An Approach To Minimising Risk Of Adrenal Insufficiency When Discontinuing Oral Glucocorticoids

Mathew N. Nicholas, Stephanie K Li, Marlene T Dytoc
Published 2018 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Oral glucocorticoids are commonly used across every field of medicine; however, discontinuing them in patients can be challenging. The risk of acute adrenal crises secondary to glucocorticoid withdrawal can be fatal and arises from chronic suppression of the adrenal glands. Identifying risk factors for adrenal suppression in dermatological patients, such as doses greater than 5 to 7.5 mg of prednisone equivalent, duration of glucocorticoid use greater than 3 weeks, certain medications, and comorbidities, can help risk-stratify patients. The use of adrenal gland testing such as basal cortisol levels and adrenocorticotropic hormone stimulation tests can confirm adrenal suppression in patients. This review article provides an approach that dermatologists can use to minimise the risk of adrenal insufficiency in patients discontinuing glucocorticoids and when it may be appropriate to use adrenal gland testing.
This paper references
10.1056/NEJM194501042320101
The Waterhouse-Friderichsen Syndrome
V. C. D'agati (1945)
10.1177/014107688708000709
Adrenal Suppression following Low-Dose Topical Clobetasol Propionate
E M Ohman (1987)
10.5694/j.1326-5377.2008.tb02069.x
Management of adrenal insufficiency during the stress of medical illness and surgery.
Ian J. Woodforth (2008)
Glucocorticoid withdrawal
D Furst
10.4158/EP10095.RA
Endocrine involvement in systemic amyloidosis.
Didem Ozdemir (2010)
10.1038/ncpendmet0921
The altered adrenal axis and treatment with glucocorticoids during critical illness
Dieter Mesotten (2008)
10.3899/jrheum.130019
We Still Don’t Know How to Taper Glucocorticoids in Rheumatoid Arthritis, and We Can Do Better
Elizabeth R Volkmann (2013)
Adrenal Suppression
M Lansang (2016)
10.2310/7750.2008.07029
Side Effects of Short-Term Oral Corticosteroids
Robert N. Richards (2008)
10.1016/S0889-8529(03)00008-2
Perioperative management of patients treated with glucocorticoids.
Lloyd Axelrod (2003)
10.1056/NEJMra0804635
Predisposing factors for adrenal insufficiency.
Stefan R. Bornstein (2009)
10.1210/jcem.80.4.7714104
The role of the low dose (1 microgram) adrenocorticotropin test in the evaluation of patients with pituitary diseases.
Karen M Tordjman (1995)
10.1056/NEJM199201233260403
The Effect of Long-Term Glucocorticoid Therapy on Pituitary–Adrenal Responses to Exogenous Corticotropin-Releasing Hormone
Reiner Schlaghecke (1992)
10.2169/internalmedicine.55.5392
Sarcoidosis Presenting Addison's Disease.
Kentaro Takahashi (2016)
10.7861/clinmedicine.8-2-211
Adrenal insufficiency.
Wiebke Arlt (2003)
10.1210/jc.2015-1700
ACTH Stimulation Tests for the Diagnosis of Adrenal Insufficiency: Systematic Review and Meta-Analysis.
Naykky M Singh Ospina (2016)
10.1007/s40618-016-0451-7
Endocrine dysfunction in hereditary hemochromatosis
Carla Pelusi (2016)
10.1002/PSB.1060
How to manage withdrawal of glucocorticoid therapy
Amalia Iliopoulou (2013)
[Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis].
Leonie H A Broersen (2015)
10.1046/j.1529-8019.2002.01538.x
Glucocorticoids in the treatment of bullous diseases
Danielle Dehoratius (2002)
10.1056/NEJM199710303371807
Corticosteroid therapy in severe illness.
Steven W.J. Lamberts (1997)
Glucocorticoid withdrawal. https://www.uptodate.com/contents/glucocorticoid-withdrawal
D Furst (2016)
10.1046/j.1365-2265.2000.00984.x
Low-dose (1 μg) adrenocorticotrophin (ACTH) stimulation as a screening test for impaired hypothalamo-pituitary-adrenal axis function : sensitivity, specificity and accuracy in comparison with the high-dose (250 μg) test
Karen M Tordjman (2000)
10.4158/EP14503.RA
Genetic forms of adrenal insufficiency.
Elise M. Brett (2015)
10.1055/s-0029-1225630
Diagnosis of secondary adrenal insufficiency: unstimulated early morning cortisol in saliva and serum in comparison with the insulin tolerance test.
Timo Deutschbein (2009)
10.7326/0003-4819-61-1-11
PROBABILITIES OF PITUITARY-ADRENAL RESPONSIVENESS AFTER STEROID THERAPY.
Thaddeus S. Danowski (1964)
10.1111/1346-8138.13071
Yearly reduction of glucocorticoid dose by 50% as tapering schedule achieves complete remission for 124 pemphigus vulgaris patients.
Mingyue Wang (2016)
Low-dose (1 microgram) adrenocorticotrophin (ACTH) stimulation as a screening test for impaired hypothalamo-pituitary-adrenal axis function: sensitivity, specificity and accuracy in comparison with the high-dose (250 microgram) test.
Karen M Tordjman (2000)
10.1210/jcem-72-1-39
Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry.
Nora Valeiras Esteban (1991)
Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones
BP Schimmer (2006)
10.1016/j.ejim.2013.05.014
Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself.
Stina Dinsen (2013)
10.1111/j.1365-2265.1987.tb00780.x
Value of basal plasma cortisol assays in the assessment of pituitary-adrenal insufficiency.
Erik Hägg (1987)
Comprehensive Dermatologic Drug Therapy
Stephen E Wolverton (2001)
10.1002/art.20884
Evaluation of the pituitary-adrenal axis function following single intraarticular injection of methylprednisolone.
Reuven Mader (2005)
10.1007/s12098-008-0208-1
Corticosteroid physiology and principles of therapy
Priyanka Gupta (2008)
The WaterhouseFriderichsen syndrome
D’Agati VCM (1945)
10.1097/00004836-200110000-00006
Side Effects of Corticosteroid Therapy
Alan L. Buchman (2001)



Semantic Scholar Logo Some data provided by SemanticScholar